Rethink: Payer Strategies for Commercializing Cell and Gene Therapies

By AmerisourceBergen |

Insights from managed care executives on the future of coverage and outcomes evaluation.

Cell and gene therapies present a new frontier for medical advances. But with that frontier comes a host of new questions about how to gain coverage for products to drive access and ensure a clear path to treatment. Xcenda surveyed 46 executives from managed care organizations, pharmacy benefit managers and similar organizations to discover how they are evaluating the cell and gene therapy space. The insights show a market that’s not yet fully aligned around how it will approach coverage for cell and gene therapy products—which presents ample opportunities for cell and gene therapy innovators to shape payers’ thoughts and decision-making in this burgeoning therapeutic class.